2026-01-22 - Analysis Report
**Report: Johnson & Johnson (JNJ) Analysis**

**Company Overview:**
Johnson & Johnson is a multinational healthcare company that develops and markets a wide range of pharmaceuticals, medical devices, and consumer packaged goods.

**Return Rate Comparison:**

| Ticker | Cumulative Return | Rate | Rate_vs | Divergence |
| --- | --- | --- | --- | --- |
| JNJ | 60.16% | N/A | 91.55% (VOO) | -32.70, 39.00% |

The cumulative return of JNJ is 60.16%, lower than the S&P 500 (91.55%) by 31.39%.

**Alpha, Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 6.0% | 16.8% | 2.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -49.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

**Recent Stock Price Fluctuations:**

| Metric | Value |
| --- | --- |
| Close | $218.01 |
| Last-market | -$0.20 (-0.09%) |
| 5-day SMA | $218.60 (+0.25%) |
| 20-day SMA | $210.02 (-3.60%) |
| 60-day SMA | $202.80 (-6.80%) |

**Indicator Analysis:**

| Metric | Value |
| --- | --- |
| RSI | 70.94 |
| PPO | 0.46 |
| MRI | 0.80 |
| Relative Divergence Change | +14.60 |
| 7-day Rank Change | +30 |
| 7-day Dynamic Expected Return Change | -1.30 |
| Expected Return | -38.60% |
| Expected Excess Return | N/A |

**Recent News & Significant Events:**

Please find the recent news and significant events below:

* How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily (news.google.com)
* J&J stock drops after Q4 2025 results (JNJ:NYSE) - Seeking Alpha (news.google.com)
* JNJ Earnings: Johnson & Johnson Stock Falls Despite Q4 Revenue Beat - TipRanks (news.google.com)
* J&J's 2026 guidance driven by 'exciting' new product story - Yahoo Finance (news.google.com)
* Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. - Barron's (news.google.com)
* Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Hereâ€™s How to Buy Without the Risk - TipRanks (news.google.com)

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 212.00 / 240.00 / 155.00

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |

JNJ's EPS is increasing, while revenue is fluctuating around $22B-$24B.

**Financial Information: Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Revenue is fluctuating around $22B-$23B, with profit margin between 66.40%-69.56%.

**Financial Information: Capital and Profitability:**

| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

Equity is fluctuating around $70B-$80B, with ROE between 3.84%-14.08%.

**Comprehensive Analysis:**
Based on the above analysis, JNJ is showing a mixed performance, with revenue and profit margin fluctuating around $22B-$23B and 66.40%-69.56%, respectively. The stock price is showing a bearish trend, with a 20-day SMA of $210.02 and a 60-day SMA of $202.80. The MRI is indicating a medium investment risk level, while the expected return is -38.60%. The analyst consensus is indicating a buy rating, with a mean rating of 2.16 and target price of $212.00.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.